secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001213900-24-023571
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed enters $75M at-the-market equity facility, terminates prior Cantor agreement
--------------------------------------------------------------------------------

- ATM agreement with Rodman & Renshaw and StockBlock Securities for up to $75M of common stock.
- Prior Cantor Fitzgerald ATM (up to $100M) terminated March 17, 2024; net proceeds from it were ~$26.25M.
- Agents receive 3.0% commission on gross proceeds; Company has no obligation to sell shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390024023571/0001213900-24-023571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390024023571/ea0201743-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-023571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer